BSH 2017 | New trials in relapsed high-grade lymphomas
Graham Collins
Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, from the Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses new clinical trials in relapsed high-grade lymphomas at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. He speaks about a planned trial of the PD-1 inhibitor nivolumab as a bridge to stem cell transplantation in relapsed Hodgkin Lymphoma. In high-grade lymphoma, Dr Collins is running the TORCH trial (NCT02752204) of the next-generation mTOR inhibitor vistuserib in relapsed diffuse large B-cell lymphoma. He also highlights the potential of rational combination therapies in relapsed high-grade lymphomas.
Related videos
1:22
Update on CAR T-cell therapy at the City of Hope
Steven Rosen
6:32
Pathobiology and clinical management of T-cell lymphoma
Francine Foss
et al.
3:11
CD47-targeting antibody: targeting the source of non-Hodgkin lymphoma
Irving Weissman
9:57
Cellular therapy and drug access for viral lymphomas
Catherine Bollard
et al.
8:24
Viral lymphomas: risk factors and treatments
Catherine Bollard
et al.
